2496892

Modulation of GFAP mRNA levels following toxic lesions in the basal ganglia of the rat.

Article date: 1989/1/1

PubMed ID: 2496892

Journal name: Brain research bulletin (ISSN: 0361-9230)

ABSTRACT

GFAP mRNA levels were quantified by Northern blot analysis using a human GFAP (glial fibrillary acidic protein) cDNA probe in association with immunocytochemistry. Ten days after a unilateral lesion of substantia nigra with 6-hydroxydopamine (6-OHDA), GFAP mRNA level is increased 1.4-fold in the ipsilateral striatum; thereafter it declined continuously to reach the control level 4 months later. This effect contrasted with the lower and more sustained increase of preproenkephalin (PPE) mRNA, a marker of neuronal target of nigrostriatal pathway. Following ibotenic acid-induced neuronal degeneration of the neostriatum in the rat, we observed a sharp elevation of the GFAP transcripts (4-fold) as soon as 2 days after the lesion both in the striatum and in the substantia nigra. Whereas in the striatum GFAP mRNA level already declined at 5 days postlesion, it remained stable in the substantia nigra. In comparison GFAP immunoreactivity was slightly delayed. No obvious modification was observed in the contralateral side to the lesion whatever the denervation condition studied. Implication of these results on the understanding and the therapeutic approach of glial scarring is discussed.

Author List: Rataboul P, Vernier P, Biguet N F, Mallet J, Poulat P, Privat A

Publication Types: Journal Article; Research Support, Non-U.S. Gov't

Substances mentioned in the article: Glial Fibrillary Acidic Protein; Hydroxydopamines; Oxazoles; RNA, Messenger; Ibotenic Acid; Oxidopamine;

Mesh terms: Animals; Astrocytes/drug effects; Corpus Striatum/cytology; Glial Fibrillary Acidic Protein/genetics; Hydroxydopamines; Ibotenic Acid; Male; Oxazoles; Oxidopamine; RNA, Messenger/metabolism; Rats; Rats, Inbred Strains; Substantia Nigra/cytology;

2496892.txt · Last modified: 2018/11/20 14:26 (external edit)